These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 7219836)

  • 21. Lack of effect of a new spasmolytic agent, rociverine, on intraocular pressure, pupil size and iridocorneal angle in patients with angle-closure glaucoma.
    Pardini M; Saponati G
    Pharmatherapeutica; 1983; 3(7):445-50. PubMed ID: 6669589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Colic and spastic states of the urinary tract. Comparison between syntropium bromide (VAL 480) with ioscine n-butylbromide and with noramidopyrine-pitofenone-fenpiverinium bromide].
    Colpi GM; Politi P; Sandri S; Fanciullacci F; Biraghi M; Zanollo A
    Minerva Urol Nefrol; 1985; 37(3):341-8. PubMed ID: 3911456
    [No Abstract]   [Full Text] [Related]  

  • 23. Rociverine compared with other spasmolytics for cardiovascular effects.
    Guelfi M; Schiantarelli P; Subissi A
    Farmaco Prat; 1981 Aug; 36(8):374-82. PubMed ID: 7274417
    [No Abstract]   [Full Text] [Related]  

  • 24. Investigation of rociverine + dipyrone for antispasmodic and analgesic interactions.
    Schiantarelli P; Murmann W; Magi S
    Arzneimittelforschung; 1979; 29(5):760-5. PubMed ID: 582975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rociverine citrate: a new spasmolytic agent, potentially useful in the treatment of urinary bladder hyperreflexia.
    Subissi A; Maggi CA; Meli A
    Jpn J Pharmacol; 1986 Oct; 42(2):153-7. PubMed ID: 3540391
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bicifadine: non-narcotic analgesic activity of 1-aryl-3-azabicyclo[3.1.0] hexanes.
    Epstein JW; Osterberg AC; Regan BA
    NIDA Res Monogr; 1982 Apr; 41():93-8. PubMed ID: 6811945
    [No Abstract]   [Full Text] [Related]  

  • 27. [Clinical evaluation of a new spasmolytic: sintropium bromide (VAL 480) in spastic states of the upper and lower urinary tract].
    Colosi V; Arcidiacono G; Mignosa E; Biraghi M
    Minerva Urol Nefrol; 1986; 38(3):271-8. PubMed ID: 3810389
    [No Abstract]   [Full Text] [Related]  

  • 28. [Value of the rapid perfusion of Spasfon in high doses in dynamic dystocia and anomalies of dilatation].
    Hourcabie J; Ambonville C; Albalat F; Becat A
    J Gynecol Obstet Biol Reprod (Paris); 1976 Sep; 5(6):847-8. PubMed ID: 1026765
    [No Abstract]   [Full Text] [Related]  

  • 29. Effects of rociverine on the human ureter: in vivo and in vitro experimental study.
    Potenzoni D; Zappia L; Sacchini P; Bezzi E
    Pharmacol Res Commun; 1984 Aug; 16(8):765-74. PubMed ID: 6494219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Medical therapy of ureteral colic. A comparative clinical study of 3 spasmolytics, 1 of which is combined with an analgesic].
    Borelli A; Roversi P; Palmieri B; Saponati G; Gallo M
    Minerva Urol Nefrol; 1984; 36(3):253-60. PubMed ID: 6152502
    [No Abstract]   [Full Text] [Related]  

  • 31. [Effect of mebikar on focal epileptic activity].
    Rekhtman MB; Torshin VI; Darinskiĭ NV
    Biull Eksp Biol Med; 1981 Feb; 91(2):178-81. PubMed ID: 7225554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rociverine, a new antispasmodic agent with balanced neurotropic and myotropic activity.
    Toson G; Schiantarelli P; Murmann W
    Arzneimittelforschung; 1978; 28(7):1130-42. PubMed ID: 582702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of rociverine and other spasmolytic agents on caerulein-induced delay in gastric emptying in the conscious rat.
    Subissi A; Guelfi M
    Arch Int Pharmacodyn Ther; 1982 May; 257(1):130-7. PubMed ID: 7114969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapeutic study of a new antispasmodic current gynecologic and obstetrical practice].
    Harmeau
    Gynecol Prat; 1968; 19(1):45-9. PubMed ID: 5748206
    [No Abstract]   [Full Text] [Related]  

  • 35. [1-ethoxysilatrane--an inhibitor of the development of experimental atherosclerotic lesion of the aorta].
    Konova NS; Pertsovskiĭ AI; Voronkov MG
    Dokl Akad Nauk SSSR; 1984; 276(3):757-9. PubMed ID: 6468268
    [No Abstract]   [Full Text] [Related]  

  • 36. [Effect of exogenous superoxide dismutase and 1,4-diazobicyclo-(2,2,2,)-octane on the resistance of mice to acute oxygen poisoning].
    Gerasimov AM; Gusev VA; Brusov OS
    Biull Eksp Biol Med; 1977 Feb; 83(2):147-50. PubMed ID: 851614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of mebikar on the state of animals under extreme conditions].
    Zimakova IE; Kamburg RA; Kirshin SV
    Farmakol Toksikol; 1980; 43(4):368-71. PubMed ID: 7439369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical experimentation with a new antispasmodic agent in obstetrics and gynecology: A.118].
    Anglade JP; Bertrand J; Monteil R
    Therapie; 1971; 26(4):713-22. PubMed ID: 5119124
    [No Abstract]   [Full Text] [Related]  

  • 39. [Effect of mebikar on the experimental and clinical course of traumatic shock].
    Bazarevich GIa; Zimakova IE; Kharin GM; Katkovskiĭ GB; Lazareva LV
    Vestn Khir Im I I Grek; 1981 Jul; 127(7):81-5. PubMed ID: 7292861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Correlation between the stress-protective and vegetotropic action of mebikar].
    Val'dman AV; Zaikonnikova IV; Kozlovskaia MM; Zimakova IE; Bravkov MF
    Farmakol Toksikol; 1981; 44(1):47-9. PubMed ID: 7196343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.